866862-23-9

Basic information

• Product Name: 3-bromo-4-fluorobenzyl metanesulfonate
• Synonyms: 3-bromo-4-fluorobenzyl metanesulfonate
• CAS NO: 866862-23-9
• Molecular Weight: 283.118
• Mol File: 866862-23-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-bromo-4-fluorobenzyl metanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-4-fluorobenzyl metanesulfonate(866862-23-9)
• EPA Substance Registry System: 3-bromo-4-fluorobenzyl metanesulfonate(866862-23-9)

Safety Data

• Hazardous Substances Data: 866862-23-9(Hazardous Substances Data)

Upstream product

• 77771-02-9 3-bromo-4-fluorobenzaldehyde 
• 77771-03-0 3-bromo-4-fluoro-benzyl alcohol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 501420-63-9 2-(3-bromo-4-fluoro-phenyl)acetonitrile 
• 887268-22-6 2-bromo-1-fluoro-4-(methoxymethyl)benzene 
• 929885-07-4 C₁₀H₈BrFN₂ 

Relevant articles and documents

A Series of Analogues to the AT2R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode

We here report on our continued studies of ligands binding to the promising drug target angiotensin II type 2 receptor (AT2R). Two series of compounds were synthesized and investigated. The first series explored the effects of adding small subs

Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases

New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aimed at reducing serum protein binding led to the identification of several compounds that showed not only excellent affinities for the receptor (41 compounds with Ki 50 100 nM; PGD2-induced eosinophil shape change). Additional optimization of the PK characteristics led to the identification of several compounds suitable for in vivo testing. Of these, 19k and 19s were tested in two different pharmacological models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).

PHENOXY ACETIC ACID DERIVATIVES

The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.